David Lazar

Form D signer

David Lazar

Interim Chief Executive Officer at Cyclacel Pharmaceuticals

Form D signer

Capital raised by Cyclacel Pharmaceuticals

$1.0M+$1.0M latest round

3 Form D filings · first filed Feb 2025 · Berkeley Heights, NJ

CURRENT ROLE: Interim Chief Executive Officer
SECTOR: Biotech
COMPANY FILINGS: 3
TEAM ON FILE: 4
FOUNDED: —
30D INTEREST: 1 ↗

Career

1 company on file

Cyclacel PharmaceuticalsBiotech · Berkeley Heights, NJsince Feb 2025

Interim Chief Executive Officer

Signatory on Cyclacel Pharmaceuticals's Form D filings · $1.0M raised across 3

Company filings

via EDGAR · Form D for Cyclacel Pharmaceuticals3

DateCompanyFormAmountRole on filing

Mar 21, 2025Cyclacel PharmaceuticalsForm D+$1.0MInterim Chief Executive Officer

Form DMar 21, 2025 · Cyclacel Pharmaceuticals+$1.0Mas Interim Chief Executive Officer

Feb 14, 2025Cyclacel PharmaceuticalsForm D—Interim Chief Executive Officer

Form DFeb 14, 2025 · Cyclacel Pharmaceuticals—as Interim Chief Executive Officer

Feb 6, 2025Cyclacel PharmaceuticalsForm D—Interim Chief Executive Officer

Form DFeb 6, 2025 · Cyclacel Pharmaceuticals—as Interim Chief Executive Officer

Overview

Last filing Mar 21, 2025

David Lazar is on file as Interim Chief Executive Officer at Cyclacel Pharmaceuticals in Berkeley Heights, NJ. Cyclacel Pharmaceuticals has 3 Form D filings on record, $1.0M raised in total. David Lazar appears as a signatory on the company's filings.

Teammates

Cyclacel Pharmaceuticals · 3

Avraham Ben-TzviDirector Datuk Dr.Doris Wong Sing EeChief Executive OfficerSigner Samuel BarkerDirector

Products

Cyclacel Pharmaceuticals · 1

Novel Oncology TreatmentsOncology

Cyclacel Pharmaceuticals develops a range of therapeutic candidates aimed at overcoming cancer drug resistance utilizing targeted approaches in cell cycle biology, transcriptional regulation, and mitosis biology. These innovative treatments are designed to tackle cancers that have proven challenging for conventional therapies.